跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
陳 瓏方
主治醫師
,
臺北市立萬芳醫院
https://orcid.org/0000-0002-7505-2791
電子郵件
104210
w.tmu.edu
tw
h-index
117
引文
5
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2015
2022
每年研究成果
概覽
指紋
網路
研究成果
(9)
類似的個人檔案
(7)
指紋
查看啟用 Lung-Fang Chen 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Immunology and Microbiology
Action Potential
15%
Anti-Citrullinated Protein Antibody
47%
Antibody Titer
15%
Arthritis
47%
Autoantibodies
15%
Autoimmune Rheumatic Disease
47%
Axon
15%
Biological Product
9%
C-Reactive Protein
47%
Ciclosporin
9%
Comorbidity
19%
Cyclophosphamide
14%
Dermatomyositis
19%
Electronic Medical Record
7%
Excitability
15%
Gout
47%
Human Immunodeficiency Virus Infection
9%
Inflammatory Arthritis
100%
La Antibody
47%
Methotrexate
9%
Monospecific Antibody
15%
Muscle Action Potential
15%
Mycophenolic Acid
14%
Nerve Conduction
15%
Nerve Excitability
15%
Nerve Fiber
31%
Oligoarthritis
6%
Periosteum
6%
Peripheral Nerve
15%
Pneumocystis Jiroveci
47%
Polymyositis
19%
Population
9%
Prevalence
6%
Refractory Period
31%
Sensory Nerve
31%
Sjögren's Syndrome
9%
Subcutaneous Tissue
13%
Synovitis
47%
Synovium
6%
Systemic Lupus Erythematosus
9%
Systemic Scleroderma
9%
Titer
15%
Tocilizumab
7%
Vascularization
6%
Pharmacology, Toxicology and Pharmaceutical Science
Antihistaminic Agent
38%
Biological Product
9%
Ciclosporin
9%
Comorbidity
19%
Cyclophosphamide
14%
Dermatomyositis
19%
Dose-Response Relationship
8%
Hepatitis B Virus
47%
Hepatitis C
47%
Hepatitis C Virus
47%
Histamine H1 Receptor Antagonist
47%
Human Immunodeficiency Virus Infection
9%
Immunosuppressive Agent
9%
Interstitial Lung Disease
9%
Liver Cell Carcinoma
47%
Malignant Neoplasm
9%
Methotrexate
9%
Mycophenolic Acid
14%
Pneumocystis Jiroveci
47%
Polymyositis
19%
Rheumatic Disease
47%
Sjoegren Syndrome
9%
Systemic Lupus Erythematosus
9%
Systemic Sclerosis
9%
Virus Hepatitis
47%
Virus Infection
8%
Medicine and Dentistry
Action Potential
15%
Afferent Nerve Fiber
31%
Autoantibodies
15%
Autoimmune Rheumatic Disease
47%
Axon
15%
Biological Product
9%
Clinical Trial
15%
Compound Muscle Action Potential
15%
Cyclophosphamide
14%
Cyclosporine
9%
Dermatomyositis
19%
Drug Therapy
9%
Excitability
15%
Human Immunodeficiency Virus Infection
9%
Interstitial Lung Disease
9%
La Antibody
47%
Methotrexate
9%
Mycophenolic Acid
14%
Nerve Conduction Study
15%
Nerve Excitability
15%
Nerve Fiber
31%
Pathophysiology
15%
Peripheral Nerve
15%
Peripheral Neuropathy
15%
Pneumocystis Jirovecii
47%
Polymyositis
19%
Population
9%
Proportional Hazards Model
9%
Refractory Period
31%
Rheobase
15%
Sjoegren Syndrome
9%
Systemic Lupus Erythematosus
9%
Systemic Scleroderma
9%
